

applications to this subject matter. New claims 19-25 recite preferred embodiments of the elected claim group and should be examined with the elected claims. Claim 19 recites that the peptide is present in a therapeutically effective amount (Specification at page 2 and Examples). Claim 20 recites the compositions in aqueous solution (Specification, *e.g.*, at page 2, line 8). Claim 21 recites that the sustained release formulation or device includes at least one of a biodegradable polymer incorporating the peptide or an implantable osmotic pump (Specification, *e.g.*, at page 2, lines 11-15). Claim 22 recites a growth-hormone reducing composition including the peptide (Specification, *e.g.*, at pages 2-3). Claims 23-24 recite compositions adapted for intrapulmonary or intranasal administration and in correspondingly effective amounts of the peptide (Specification, *e.g.*, at page 2, lines 11-12). Claim 25 recites an embodiment of the peptide with a carrier in an amount effective to normalize or reduce an elevated growth hormone level in a patient (Specification, *e.g.*, at pages 2-3). No new matter is believed to have been added by these new claims, such that all pending claims should be entered and examined at this time.

Applicants also submit a Supplemental Declaration herewith, executed by the inventor, to correct a typographical error in the filing date of the priority claim.

No fee is believed to be due for this submission. Should any fees be required, please charge such required fees to Winston & Strawn Deposit Account No. 501-814.

Respectfully submitted,

10/28/02

Date


Jeffrey A. Wolfson (Reg. No. 42,234)
For: Allan A. Fanucci (Reg. No. 30,256)

WINSTON & STRAWN
Customer No.: 28765

(202) 371-5770

APPENDIX A: MARKED UP AMENDED CLAIMS

2. (Amended) The peptide of claim 1 [specifically as] wherein the formula is Gly-Ser-Ser(Octanoyl)-Phe-Leu-Ser-Pro-Glu.
3. (Amended) The peptide of claim 1 [specifically as] wherein the formula is Gly-Ser-Ser(Octanoyl)-Phe-Leu-Ser-Pro-Glu-Ala-Lys-Leu-Gln-Pro-Arg.
4. (Amended) The peptide of claim 1 [specifically as] wherein the formula is Gly-Ser-Ser(Octanoyl)-Phe.
5. (Amended) A pharmaceutical composition comprising the peptide of claim 1 in the form of a pharmaceutically acceptable salt.

APPENDIX B: FULL SET OF PENDING CLAIMS

1. A Ghrelin antagonist peptide of the formula:

Gly-Ser-Ser(Octanoyl)-Phe-A

where A is -OH, NH₂, Leu-Ser-Pro-Glu-B, or -Ala-Lys-Leu-Gln-Pro-Arg-B, where B is -OH or NH₂, wherein said peptide antagonizes the effect of ghrelins when administered to a mammal.

2. (Amended) The peptide of claim 1 wherein the formula is Gly-Ser-Ser(Octanoyl)-Phe-Leu-Ser-Pro-Glu.

3. (Amended) The peptide of claim 1 wherein the formula is Gly-Ser-Ser(Octanoyl)-Phe-Leu-Ser-Pro-Glu-Ala-Lys-Leu-Gln-Pro-Arg.

4. (Amended) The peptide of claim 1 wherein the formula is Gly-Ser-Ser(Octanoyl)-Phe.

5. (Amended) A pharmaceutical composition comprising the peptide of claim 1 in the form of a pharmaceutically acceptable salt.

6. The composition of claim 5 which further comprises a carrier.

7. The composition of claim 5 in the form of a sustained release formation or device for parenteral administration.

8. The peptide of claim 5 in the form of a pharmaceutically acceptable intranasal formulation.

9. The peptide of claim 5 in the form of a pharmaceutically acceptable inhalation formulation.

- 10-18. Canceled.

19. (New) The composition of claim 5, wherein the peptide is present in a therapeutically effective amount.

20. (New) An aqueous solution comprising the composition of claim 19.

21. (New) The composition of claim 7, wherein the sustained release formulation or device comprises at least one of a biodegradable polymer incorporating the peptide or an implantable osmotic pump.

22. (New) A growth-hormone reducing composition comprising the peptide of claim 1.

23. (New) An inhalable composition comprising an intrapulmonary effective amount of the peptide of claim 1.

24. (New) An intranasal composition comprising an intranasally effective amount of the peptide of claim 1.

25. (New) An Ghrelin antagonist peptide composition comprising:
Gly-Ser-Ser(Octanoyl)-Phe-A, where A is -OH, NH₂, Leu-Ser-Pro-Glu-B, or -
Ala-Lys-Leu-Gln-Pro-Arg-B, where B is -OH or NH₂; and
at least one carrier or excipient,
wherein the peptide is present in an amount effective to normalize or reduce an elevated growth hormone level in a patient.